The sustained double-digit revenue growth, particularly in Tyvaso DPI, combined with strong profitability and ongoing share repurchases, suggests continued momentum. Traders should monitor the upcoming ADVANCE OUTCOMES and TETON-1 clinical trial readouts as potential catalysts for further upside.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 25 $534.37entry
- T+1 · 9mo ago −5.84%α −5.29% · $503.18
- T+5 · 9mo ago −8.78%α −7.68% · $487.47
- T+20 · 8mo ago +1.28%α +6.52% · $541.22
- T+60 · 6mo ago +5.53%α −1.42% · $563.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
United Therapeutics reported record full-year 2025 revenue of $3.18 billion, up 11% year-over-year, driven by strong performance from Tyvaso DPI and Orenitram. Net income increased to $1.33 billion, and the company maintained its share repurchase program with $2 billion in accelerated buybacks. Management reaffirmed expectations for durable double-digit revenue growth.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue reached $3.18 billion, up 11% from $2.88 billion in 2024
- Tyvaso DPI revenue grew 25% to $1.29 billion, driven by patient growth and Medicare Part D benefit redesign
- Net income increased 12% to $1.33 billion, with diluted EPS of $27.86
- Company executed $2 billion in accelerated share repurchases ($1 billion in August 2025 and $1 billion in March 2024)
- Management maintained guidance for durable double-digit revenue growth
Financial Impact
Revenue growth of $305.3 million and net income growth of $139.6 million year-over-year
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Tyvaso DPI | $1.3K | +25.0% |
| Orenitram | $496.90 | +14.0% |
| Remodulin | $526.80 | -2.0% |
Risk Factors
- Revenue declines in Remodulin (-2% YoY) and Unituxin (-5% YoY) could indicate product lifecycle challenges
- Increased R&D spending (up 14% to $550 million) may pressure future margins if not offset by new product approvals
- Forward-looking statements about clinical trials and revenue growth are subject to significant risks and uncertainties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001082554-26-000007 |
| Document: uthr-20260225.htm | 0001082554-26-000007 |
| Document: 0001082554-26-000007-index-headers.html | 0001082554-26-000007 |
| Document: 0001082554-26-000007-index.html | 0001082554-26-000007 |
| Document: 0001082554-26-000007.txt | 0001082554-26-000007 |
Track record
123 reports on UTHR
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 4 of 8 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $587.88 Now $587.88 +0.00% settles Nov 24
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers